The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Fluoroquinolones and Biofilm: A Narrative Review
Abstract
Background: Biofilm-associated infections frequently span multiple body sites and represent a significant clinical challenge, often requiring a multidisciplinary approach involving surgery and antimicrobial therapy. These infections are commonly healthcare-associated and frequently related to internal or external medical devices. The formation of biofilms complicates treatment, as they create environments that are difficult for most antimicrobial agents to penetrate. Fluoroquinolones play a critical role in the eradication of biofilm-related infections. Numerous studies have investigated the synergistic potential of combining fluoroquinolones with other chemical agents to augment their efficacy while minimizing potential toxicity. Comparative research suggests that the antibiofilm activity of fluoroquinolones is superior to that of beta-lactams and glycopeptides. However, their activity remains less effective than that of minocycline and fosfomycin. Noteworthy combinations include fluoroquinolones with fosfomycin and aminoglycosides for enhanced activity against Gram-negative organisms and fluoroquinolones with minocycline and rifampin for more effective treatment of Gram-positive infections. Despite the limitations of fluoroquinolones due to the intrinsic characteristics of this antibiotic, they remain fundamental in this setting thanks to their bioavailability and synergisms with other drugs. Methods: A comprehensive literature search was conducted using online databases (PubMed/MEDLINE/Google Scholar) and books written by experts in microbiology and infectious diseases to identify relevant studies on fluoroquinolones and biofilm. Results: This review critically assesses the role of fluoroquinolones in managing biofilm-associated infections in various clinical settings while also exploring the potential benefits of combination therapy with these antibiotics. Conclusions: The literature predominantly consists of in vitro studies, with limited in vivo investigations. Although real world data are scarce, they are in accordance with fluoroquinolones’ effectiveness in managing early biofilm-associated infections. Also, future perspectives of newer treatment options to be placed alongside fluoroquinolones are discussed. This review underscores the role of fluoroquinolones in the setting of biofilm-associated infections, providing a comprehensive guide for physicians regarding the best use of this class of antibiotics while highlighting the existing critical issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Underdosing and overuse have been identified as key factors accelerating this process.”
From Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms (2025) · cites this paper as [239]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1581st · Cited by 3,657
Practice Guidelines for the Management of Bacterial Meningitis
Tunkel, A. R., Hartman, B. J., Kaplan, S. L., Kaufman, B. A., Roos, K. L., Scheld, W. M., & Whitley, R. J. (2004) · Clinical Infectious Diseases · doi:10.1086/425368 · Cited by 2,308
Anderl, J. N., Franklin, M. J., & Stewart, P. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.7.1818-1824.2000 · Cited by 958
Human colon mucosal biofilms from healthy or colon cancer hosts are carcinogenic
Tomkovich, S., Dejea, C. M., Winglee, K., Drewes, J. L., Chung, L., Housseau, F., Pope, J. L., Gauthier, J., Sun, X., Mühlbauer, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124196 · Cited by 209
Research works printed but not linked: 233
- Tdm, 2019, Quinolone Antibiotics, MedChemComm, 10, 1719, 10.1039/C9MD00120D · DOI · Paper page
- Adjei, 2007, Identification of Metabolites Produced from N-Phenylpiperazine by Mycobacterium Spp., J. Ind. Microbiol. Biotechnol., 34, 219, 10.1007/s10295-006-0189-x · doi:10.1007/s10295-006-0189-x
- Andersson, 2003, Development of the Quinolones, J. Antimicrob. Chemother., 51, 1, 10.1093/jac/dkg212 · DOI
- Marrie, 1982, A Scanning and Transmission Electron Microscopic Study of an Infected Endocardial Pacemaker Lead, Circulation, 66, 1339, 10.1161/01.CIR.66.6.1339 · DOI · Paper page
- 2018, Biofilm-Related Disease, Expert Rev. Anti Infect. Ther., 16, 51, 10.1080/14787210.2018.1417036 · DOI · Paper page
- Rottier, 2023, Antimicrobial Treatment of Patients with a Periprosthetic Joint Infection: Basic Principles, Arthroplasty, 5, 10, 10.1186/s42836-023-00169-4 · DOI
- Willmott, 1993, A Single Point Mutation in the DNA Gyrase A Protein Greatly Reduces Binding of Fluoroquinolones to the Gyrase-DNA Complex, Antimicrob. Agents Chemother., 37, 126, 10.1128/AAC.37.1.126 · DOI · Paper page
- Brar, 2020, Fluoroquinolone Antibiotics: An Overview, Adesh Univ. J. Med. Sci. Res., 2, 26
- Bhatt, 2022, Fluoroquinolone Antibiotics: Occurrence, Mode of Action, Resistance, Environmental Detection, and Remediation—A Comprehensive Review, Environ. Pollut., 315, 120440, 10.1016/j.envpol.2022.120440 · DOI · Paper page
- Jia, 2021, The Antibacterial Activity of Fluoroquinolone Derivatives: An Update (2018-2021), Eur. J. Med. Chem., 224, 113741, 10.1016/j.ejmech.2021.113741 · doi:10.1016/j.ejmech.2021.113741
- Dewulf, 2014, Fluoroquinolone Antibiotics: An Emerging Class of Environmental Micropollutants, Sci. Total Environ., 500–501, 250
- Kabbani, 2018, Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits, Clin. Infect. Dis., 67, 134, 10.1093/cid/ciy035 · DOI
- Gelone, 2000, Fluoroquinolones, Infect. Dis. Clin. N. Am., 14, 489, 10.1016/S0891-5520(05)70260-9 · DOI
- Werner, N.L., Hecker, M.T., Sethi, A.K., and Donskey, C.J. (2011). Unnecessary Use of Fluoroquinolone Antibiotics in Hospitalized Patients. BMC Infect. Dis., 11. · DOI
- Correia, 2017, Mechanisms of Quinolone Action and Resistance: Where Do We Stand?, J. Med. Microbiol., 66, 551, 10.1099/jmm.0.000475 · DOI · Paper page
- Kohanski, 2010, How Antibiotics Kill Bacteria: From Targets to Networks, Nat. Rev. Microbiol., 8, 423, 10.1038/nrmicro2333 · DOI · Paper page
- Blondeau, 2004, Fluoroquinolones: Mechanism of Action, Classification, and Development of Resistance, Surv. Ophthalmol., 49, S73, 10.1016/j.survophthal.2004.01.005 · doi:10.1016/j.survophthal.2004.01.005
- Qu, 2021, Characterization of Lactobacillus Reuteri WQ-Y1 with the Ciprofloxacin Degradation Ability, Biotechnol. Lett., 43, 855, 10.1007/s10529-020-03068-9 · DOI
- Dube, 2023, Quinolone: A Versatile Therapeutic Compound Class, Mol. Divers., 27, 1501, 10.1007/s11030-022-10581-8 · DOI
- Zahari, N.I.N., Engku Abd Rahman, E.N.S., Irekeola, A.A., Ahmed, N., Rabaan, A.A., Alotaibi, J., Alqahtani, S.A., Halawi, M.Y., Alamri, I.A., and Almogbel, M.S. (2023). A Review of the Resistance Mechanisms for β-Lactams, Macrolides and Fluoroquinolones among Streptococcus Pneumoniae. Med. Kaunas Lith., 59. · DOI
- Xu, 2017, Moxifloxacin Is an Effective and Safe Candidate Agent for Tuberculosis Treatment: A Meta-Analysis, Int. J. Infect. Dis., 60, 35, 10.1016/j.ijid.2017.05.003 · doi:10.1016/j.ijid.2017.05.003
- Gillespie, 2016, The Role of Moxifloxacin in Tuberculosis Therapy, Eur. Respir. Rev., 25, 19, 10.1183/16000617.0085-2015 · DOI
- Saravolatz, 2019, Delafloxacin: A New Anti-Methicillin-Resistant Staphylococcus Aureus Fluoroquinolone, Clin. Infect. Dis., 68, 1058, 10.1093/cid/ciy600 · DOI
- Lee, 2022, Delafloxacin: A Review in Community-Acquired Pneumonia, Drugs, 82, 913, 10.1007/s40265-022-01725-z · DOI
- Morales, 2018, Indications for Systemic Fluoroquinolone Therapy in Europe and Prevalence of Primary-Care Prescribing in France, Germany and the UK: Descriptive Population-Based Study, Clin. Drug Investig., 38, 927, 10.1007/s40261-018-0684-7 · doi:10.1007/s40261-018-0684-7
- Kelly, 2021, Fluoroquinolone Use in a Rural Practice, Can. J. Rural. Med., 26, 14, 10.4103/cjrm.cjrm_67_20 · doi:10.4103/cjrm.cjrm_67_20
- Aminimanizani, 2001, Comparative Pharmacokinetics and Pharmacodynamics of the Newer Fluoroquinolone Antibacterials, Clin. Pharmacokinet., 40, 169, 10.2165/00003088-200140030-00003 · doi:10.2165/00003088-200140030-00003
- Sharma, 2009, Fluoroquinolone Antibacterials: A Review on Chemistry, Microbiology and Therapeutic Prospects, Acta Pol. Pharm., 66, 587
- Tulkens, 2009, Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin: Comparison with Other Fluoroquinolones and Other Antibacterial Classes, Drug Saf., 32, 359, 10.2165/00002018-200932050-00001 · DOI
- Tam, 2014, Fluoroquinolone-Induced Achilles Tendinitis, Hong Kong Med. J. Xianggang Yi Xue Za Zhi, 20, 545, 10.12809/hkmj134105 · doi:10.12809/hkmj134105
- Annisa, N., Barliana, M.I., Santoso, P., and Ruslami, R. (2022). Transporter and Metabolizer Gene Polymorphisms Affect Fluoroquinolone Pharmacokinetic Parameters. Front. Pharmacol., 13. · DOI
- Jamal, 2018, Bacterial Biofilm and Associated Infections, J. Chin. Med. Assoc., 81, 7, 10.1016/j.jcma.2017.07.012 · DOI · Paper page
- Stewart, 2014, Biophysics of Biofilm Infection, Pathog. Dis., 70, 212, 10.1111/2049-632X.12118 · DOI
- 2015, Biofilm Development, Microbiol. Spectr., 3, 51
- 2002, Understanding Bacterial Biofilms in Patients with Cystic Fibrosis: Current and Innovative Approaches to Potential Therapies, J. Cyst. Fibros., 1, 249, 10.1016/S1569-1993(02)00104-2 · DOI
- Niveditha, 2012, The Isolation and the Biofilm Formation of Uropathogens in the Patients with Catheter Associated Urinary Tract Infections (UTIs), J. Clin. Diagn. Res. JCDR, 6, 1478
- Hemmati, 2021, Novel Strategies to Combat Bacterial Biofilms, Mol. Biotechnol., 63, 569, 10.1007/s12033-021-00325-8 · DOI
- Meneses, 2023, A Systematic Review of the Use of Bacteriophages for in Vitro Biofilm Control, Eur. J. Clin. Microbiol. Infect. Dis., 42, 919, 10.1007/s10096-023-04638-1 · DOI
- Zimmerli, 2004, Prosthetic-Joint Infections, N. Engl. J. Med., 351, 1645, 10.1056/NEJMra040181 · DOI · Paper page
- Conen, 2020, Management of Neurosurgical Implant-Associated Infections, Swiss Med. Wkly., 150, w20208
- Olson, 2002, Biofilm Bacteria: Formation and Comparative Susceptibility to Antibiotics, Can. J. Vet. Res. Rev. Can. Rech. Veterinaire, 66, 86
- Hathroubi, 2018, Helicobacter Pylori Biofilm Formation and Its Potential Role in Pathogenesis, Microbiol. Mol. Biol. Rev. MMBR, 82, e00001-18, 10.1128/MMBR.00001-18 · DOI · Paper page
- Przekwas, J., Gębalski, J., Kwiecińska-Piróg, J., Wiktorczyk-Kapischke, N., Wałecka-Zacharska, E., Gospodarek-Komkowska, E., Rutkowska, D., and Skowron, K. (2022). The Effect of Fluoroquinolones and Antioxidans on Biofilm Formation by Proteus Mirabilis Strains. Ann. Clin. Microbiol. Antimicrob., 21. · DOI
- Masadeh, M.M., Alzoubi, K.H., Ahmed, W.S., and Magaji, A.S. (2019). In Vitro Comparison of Antibacterial and Antibiofilm Activities of Selected Fluoroquinolones against Pseudomonas Aeruginosa and Methicillin-Resistant Staphylococcus Aureus. Pathogens, 8. · DOI
- Balsalobre, 2012, Biofilm Infections, Their Resilience to Therapy and Innovative Treatment Strategies, J. Intern. Med., 272, 541, 10.1111/joim.12004 · DOI · Paper page
- Tunkel, 2017, 2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis, Clin. Infect. Dis., 64, e34, 10.1093/cid/ciw861 · DOI · Paper page
- Darouiche, 2004, Treatment of Infections Associated with Surgical Implants, N. Engl. J. Med., 350, 1422, 10.1056/NEJMra035415 · DOI · Paper page
- Colombo, 2022, Treatment with Cefiderocol in K. Pneumoniae KPC Nosocomial External Ventricular Drainage Meningitis: A Brief Report, Infez. Med., 30, 454
- Motta, 2014, Analysis of Complications in 430 Consecutive Pediatric Patients Treated with Intrathecal Baclofen Therapy: 14-Year Experience, J. Neurosurg. Pediatr., 13, 301, 10.3171/2013.11.PEDS13253 · doi:10.3171/2013.11.peds13253
- Soriano, 2013, Assessment of the in Vivo Formation of Biofilm on External Ventricular Drainages, Eur. J. Clin. Microbiol. Infect. Dis., 32, 1437, 10.1007/s10096-013-1895-8 · doi:10.1007/s10096-013-1895-8
- Destache, 2001, Cerebrospinal Fluid Penetration and Pharmacokinetics of Levofloxacin in an Experimental Rabbit Meningitis Model, J. Antimicrob. Chemother., 47, 611, 10.1093/jac/47.5.611 · doi:10.1093/jac/47.5.611
- Lutsar, 1998, Antibiotic Pharmacodynamics in Cerebrospinal Fluid, Clin. Infect. Dis., 27, 1117, 10.1086/515003 · DOI · Paper page
- Nau, 2010, Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections, Clin. Microbiol. Rev., 23, 858, 10.1128/CMR.00007-10 · DOI · Paper page
- Shariati, A., Arshadi, M., Khosrojerdi, M.A., Abedinzadeh, M., Ganjalishahi, M., Maleki, A., Heidary, M., and Khoshnood, S. (2022). The Resistance Mechanisms of Bacteria against Ciprofloxacin and New Approaches for Enhancing the Efficacy of This Antibiotic. Front. Public Health, 10. · DOI · Paper page
- Karvouniaris, 2022, Current Perspectives on the Diagnosis and Management of Healthcare-Associated Ventriculitis and Meningitis, Infect. Drug Resist., 15, 697, 10.2147/IDR.S326456 · DOI
- Verderosa, 2017, Ciprofloxacin-Nitroxide Hybrids with Potential for Biofilm Control, Eur. J. Med. Chem., 138, 590, 10.1016/j.ejmech.2017.06.058 · DOI
- Voinescu, 2024, A Comprehensive Review of Microbial Biofilms on Contact Lenses: Challenges and Solutions, Infect. Drug Resist., 17, 2659, 10.2147/IDR.S463779 · doi:10.2147/idr.s463779
- Borroni, D., Paytuví-Gallart, A., Sanseverino, W., Gómez-Huertas, C., Bonci, P., Romano, V., Giannaccare, G., Rechichi, M., Meduri, A., and Oliverio, G.W. (2022). Exploring the Healthy Eye Microbiota Niche in a Multicenter Study. Int. J. Mol. Sci., 23. · doi:10.3390/ijms231810229
- Borroni, 2023, Ocular Microbiome Evaluation in Dry Eye Disease and Meibomian Gland Dysfunction: Values of Variables, Exp. Eye Res., 236, 109656, 10.1016/j.exer.2023.109656 · doi:10.1016/j.exer.2023.109656
- Borrone, 2024, The Influence of Lid-Parallel Conjunctival Folds and Conjunctivochalasis on Dry Eye Symptoms with and Without Contact Lens Wear: A Review of the Literature, Ophthalmol. Ther., 13, 651, 10.1007/s40123-023-00877-9 · doi:10.1007/s40123-023-00877-9
- Chhabra, 2006, Endophthalmitis after Open Globe Injury: Microbiologic Spectrum and Susceptibilities of Isolates, Am. J. Ophthalmol., 142, 852, 10.1016/j.ajo.2006.05.024 · doi:10.1016/j.ajo.2006.05.024
- Pachigolla, 2007, Microbial Keratitis Pathogens and Antibiotic Susceptibilities: A 5-Year Review of Cases at an Urban County Hospital in North Texas, Eye Contact Lens, 33, 45, 10.1097/01.icl.0000234002.88643.d0 · doi:10.1097/01.icl.0000234002.88643.d0
- Willcox, 2023, Biofilms and Contact Lenses: Problems and Solutions, Microbiol. Aust., 44, 96, 10.1071/MA23027 · doi:10.1071/ma23027
- Donlan, 2001, Biofilms and Device-Associated Infections, Emerg. Infect. Dis., 7, 277, 10.3201/eid0702.010226 · DOI · Paper page
- Lodha, 2022, Biofilm Formation and Its Effect on the Management of Culture-Positive Bacterial Endophthalmitis, Indian J. Ophthalmol., 70, 472, 10.4103/ijo.IJO_1872_21 · doi:10.4103/ijo.ijo_1872_21
- Wozniak, 2017, Antibiotics in Ophthalmology Practice, Expert Rev. Ophthalmol., 12, 243, 10.1080/17469899.2017.1318065 · doi:10.1080/17469899.2017.1318065
- Marone, 2010, Ocular Infections: Antibiotics and Bacterial Adhesion on Biomaterials Used in Ocular Surgery, Ophthalmologica, 209, 315, 10.1159/000310649 · doi:10.1159/000310649
- Gentili, 2024, Comparison Between Moxifloxacin and Chloramphenicol for the Treatment of Bacterial Eye Infections, Curr. Ther. Res., 100, 100740, 10.1016/j.curtheres.2024.100740 · doi:10.1016/j.curtheres.2024.100740
- Diriba, K., Kassa, T., Alemu, Y., and Bekele, S. (2020). In Vitro Biofilm Formation and Antibiotic Susceptibility Patterns of Bacteria from Suspected External Eye Infected Patients Attending Ophthalmology Clinic, Southwest Ethiopia. Int. J. Microbiol., 2020. · doi:10.1155/2020/8472395
- Thirumalmuthu, 2019, Mechanisms of Fluoroquinolone and Aminoglycoside Resistance in Keratitis-Associated Pseudomonas Aeruginosa, Microb. Drug Resist. Larchmt. N, 25, 813, 10.1089/mdr.2018.0218 · DOI
- Garty, 2011, Sustained Antibiotic Release from an Intraocular Lens-Hydrogel Assembly for Cataract Surgery, Investig. Ophthalmol. Vis. Sci., 52, 6109, 10.1167/iovs.10-6071 · DOI
- Schilder, 2016, Otitis Media, Nat. Rev. Dis. Primer, 2, 16063, 10.1038/nrdp.2016.63 · DOI · Paper page
- Harmes, 2013, Otitis Media: Diagnosis and Treatment, Am. Fam. Physician, 88, 435
- Coker, 2010, Diagnosis, Microbial Epidemiology, and Antibiotic Treatment of Acute Otitis Media in Children: A Systematic Review, JAMA, 304, 2161, 10.1001/jama.2010.1651 · DOI · Paper page
- Jacobs, 1998, Prevalence of Antimicrobial-Resistant Pathogens in Middle Ear Fluid: Multinational Study of 917 Children with Acute Otitis Media, Antimicrob. Agents Chemother., 42, 589, 10.1128/AAC.42.3.589 · DOI · Paper page
- Ngo, C.C., Massa, H.M., Thornton, R.B., and Cripps, A.W. (2016). Predominant Bacteria Detected from the Middle Ear Fluid of Children Experiencing Otitis Media: A Systematic Review. PLoS ONE, 11. · DOI · Paper page
- Lampikoski, 2012, Mastoid Biofilm in Chronic Otitis Media, Otol. Neurotol. Off. Publ. Am. Otol. Soc. Am. Neurotol. Soc. Eur. Acad. Otol. Neurotol., 33, 785, 10.1097/MAO.0b013e318259533f · doi:10.1097/mao.0b013e318259533f
- Gu, 2014, Detection of Bacterial Biofilms in Different Types of Chronic Otitis Media, Eur. Arch. Oto-Rhino-Laryngol., 271, 2877, 10.1007/s00405-013-2766-8 · DOI
- Lambert, 2016, Haemophilus Influenzae Biofilm Formation in Chronic Otitis Media with Effusion, Eur. Arch. Oto-Rhino-Laryngol., 273, 3553, 10.1007/s00405-016-3958-9 · DOI
- Mittal, 2015, Current Concepts in the Pathogenesis and Treatment of Chronic Suppurative Otitis Media, J. Med. Microbiol., 64, 1103, 10.1099/jmm.0.000155 · DOI · Paper page
- Grubb, 2010, Treatment Failure, Recurrence, and Antibiotic Prescription Rates for Different Acute Otitis Media Treatment Methods, Clin. Pediatr. (Phila.), 49, 970, 10.1177/0009922810370363 · doi:10.1177/0009922810370363
- Moriyama, 2009, Formation of Biofilm by Haemophilus Influenzae Isolated from Pediatric Intractable Otitis Media, Auris. Nasus. Larynx, 36, 525, 10.1016/j.anl.2008.10.010 · DOI
- Takei, 2013, Minimal Biofilm Eradication Concentration of Antimicrobial Agents against Nontypeable Haemophilus Influenzae Isolated from Middle Ear Fluids of Intractable Acute Otitis Media, J. Infect. Chemother., 19, 504, 10.1007/s10156-013-0592-y · DOI
- Kaji, 2008, Antimicrobial Effect of Fluoroquinolones for the Eradication of Nontypeable Haemophilus Influenzae Isolates within Biofilms, Tohoku J. Exp. Med., 214, 121, 10.1620/tjem.214.121 · DOI
- Novotny, 2021, Humanized Anti-DNABII Fab Fragments Plus Ofloxacin Eradicated Biofilms in Experimental Otitis Media, Laryngoscope, 131, E2698, 10.1002/lary.29497 · DOI
- Khomtchouk, K.M., Joseph, L.I., Khomtchouk, B.B., Kouhi, A., Massa, S., Xia, A., Koliesnik, I., Pletzer, D., Bollyky, P.L., and Santa Maria, P.L. (2021). Treatment with a Neutrophil Elastase Inhibitor and Ofloxacin Reduces P. Aeruginosa Burden in a Mouse Model of Chronic Suppurative Otitis Media. NPJ Biofilms Microbiomes, 7. · DOI
- Senneville, E., Gachet, B., Blondiaux, N., and Robineau, O. (2023). Do Anti-Biofilm Antibiotics Have a Place in the Treatment of Diabetic Foot Osteomyelitis?. Antibiotics, 12. · doi:10.20944/preprints202301.0333.v1
- Almasri, D., and Dahman, Y. (2023). Prosthetic Joint Infections: Biofilm Formation, Management, and the Potential of Mesoporous Bioactive Glass as a New Treatment Option. Pharmaceutics, 15. · doi:10.3390/pharmaceutics15051401
- Trampuz, 2007, Sonication of Removed Hip and Knee Prostheses for Diagnosis of Infection, N. Engl. J. Med., 357, 654, 10.1056/NEJMoa061588 · DOI · Paper page
- Ramage, 2003, Formation of Propionibacterium Acnes Biofilms on Orthopaedic Biomaterials and Their Susceptibility to Antimicrobials, Biomaterials, 24, 3221, 10.1016/S0142-9612(03)00173-X · DOI · Paper page
- Bjarnsholt, 2015, ESCMID Guideline for the Diagnosis and Treatment of Biofilm Infections 2014, Clin. Microbiol. Infect., 21, S1, 10.1016/j.cmi.2014.10.024 · DOI · Paper page
- Høiby, N., Moser, C., Oliver, A., Williams, C., Ramage, G., Borghi, E., Azeredo, J., Macia, M.D., and European Society for Clinical Microbiology and Infectious Disease Study Group for Biofilms (ESGB) (2023). To Update or Not to Update the ESCMID Guidelines for the Diagnosis and Treatment of Biofilm Infections—That Is the Question! The Opinion of the ESGB Board. Biofilm, 6. · DOI
- Wang, L., Di Luca, M., Tkhilaishvili, T., Trampuz, A., and Gonzalez Moreno, M. (2019). Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia Coli and Pseudomonas Aeruginosa Biofilms. Front. Microbiol., 10. · DOI
- Widmer, 1991, Killing of Nongrowing and Adherent Escherichia Coli Determines Drug Efficacy in Device-Related Infections, Antimicrob. Agents Chemother., 35, 741, 10.1128/AAC.35.4.741 · DOI
- Holmberg, 2012, Effectiveness of Ciprofloxacin or Linezolid in Combination with Rifampicin against Enterococcus Faecalis in Biofilms, J. Antimicrob. Chemother., 67, 433, 10.1093/jac/dkr477 · doi:10.1093/jac/dkr477
- Fily, 2019, Moxifloxacin-Rifampicin Combination for the Treatment of Non-Staphylococcal Gram-Positive Orthopedic Implant-Related Infections, Med. Mal. Infect., 49, 540, 10.1016/j.medmal.2019.06.008 · doi:10.1016/j.medmal.2019.06.008
- Perez-Alba, E., Flores-Treviño, S., Villarreal-Salazar, V., Bocanegra-Ibarias, P., Vilchez-Cavazos, F., and Camacho-Ortiz, A. (2023). Planktonic and Biofilm States of Staphylococcus Aureus Isolated from Bone and Joint Infections and the in Vitro Effect of Orally Available Antibiotics. J. Appl. Microbiol., 134. · DOI
- Greimel, 2017, Efficacy of Antibiotic Treatment of Implant-Associated Staphylococcus Aureus Infections with Moxifloxacin, Flucloxacillin, Rifampin, and Combination Therapy: An Animal Study, Drug Des. Devel. Ther., 11, 1729, 10.2147/DDDT.S138888 · DOI
- Kalteis, 2006, Treatment of Implant-Associated Infections with Moxifloxacin: An Animal Study, Int. J. Antimicrob. Agents, 27, 444, 10.1016/j.ijantimicag.2005.12.003 · doi:10.1016/j.ijantimicag.2005.12.003
- Munaweera, 2018, Temperature-Sensitive Liposomal Ciprofloxacin for the Treatment of Biofilm on Infected Metal Implants Using Alternating Magnetic Fields, Int. J. Hyperth., 34, 189, 10.1080/02656736.2017.1422028 · DOI
- Habib, 1999, Preparation and Characterization of Ofloxacin Microspheres for the Eradication of Bone Associated Bacterial Biofilm, J. Microencapsul., 16, 27, 10.1080/026520499289284 · doi:10.1080/026520499289284
- Ferreira, 2017, Levofloxacin-Loaded Bone Cement Delivery System: Highly Effective against Intracellular Bacteria and Staphylococcus Aureus Biofilms, Int. J. Pharm., 532, 241, 10.1016/j.ijpharm.2017.08.089 · DOI
- Matos, 2015, Key-Properties Outlook of a Levofloxacin-Loaded Acrylic Bone Cement with Improved Antibiotic Delivery, Int. J. Pharm., 485, 317, 10.1016/j.ijpharm.2015.03.035 · DOI
- Sedghizadeh, P.P., Cherian, P., Roshandel, S., Tjokro, N., Chen, C., Junka, A.F., Hu, E., Neighbors, J., Pawlak, J., and Russell, R.G.G. (2023). Real-Time Impedance-Based Monitoring of the Growth and Inhibition of Osteomyelitis Biofilm Pathogen Staphylococcus Aureus Treated with Novel Bisphosphonate-Fluoroquinolone Antimicrobial Conjugates. Int. J. Mol. Sci., 24. · doi:10.3390/ijms24031985
- Sedghizadeh, 2017, Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms, J. Med. Chem., 60, 2326, 10.1021/acs.jmedchem.6b01615 · DOI
- Memar, M.Y., Ahangarzadeh Rezaee, M., Barzegar-Jalali, M., Gholikhani, T., and Adibkia, K. (2023). The Antibacterial Effect of Ciprofloxacin Loaded Calcium Carbonate (CaCO3) Nanoparticles Against the Common Bacterial Agents of Osteomyelitis. Curr. Microbiol., 80. · DOI
- Wilson, 2016, Vascular Graft Infections, Mycotic Aneurysms, and Endovascular Infections: A Scientific Statement From the American Heart Association, Circulation, 134, e412, 10.1161/CIR.0000000000000457 · DOI · Paper page
- Chiesa, 2002, Vascular Prosthetic Graft Infection: Epidemiology, Bacteriology, Pathogenesis and Treatment, Acta Chir. Belg., 102, 238, 10.1080/00015458.2002.11679305 · DOI
- Antonios, 2006, Prosthetic Vascular Graft Infection: A Risk Factor Analysis Using a Case-Control Study, J. Infect., 53, 49, 10.1016/j.jinf.2005.10.004 · doi:10.1016/j.jinf.2005.10.004
- Bandyk, 1991, In Situ Replacement of Vascular Prostheses Infected by Bacterial Biofilms, J. Vasc. Surg., 13, 575, 10.1016/0741-5214(91)90339-V · doi:10.1016/0741-5214(91)90339-v
- Sohail, 2007, Management and Outcome of Permanent Pacemaker and Implantable Cardioverter-Defibrillator Infections, J. Am. Coll. Cardiol., 49, 1851, 10.1016/j.jacc.2007.01.072 · DOI · Paper page
- Moore, 1969, Transient Bacteremia. A Cause of Infection in Prosthetic Vascular Grafts, Am. J. Surg., 117, 342, 10.1016/0002-9610(69)90368-7 · doi:10.1016/0002-9610(69)90368-7
- Gharamti, 2018, Vascular Graft Infections: An Update, Infect. Dis. Clin. North Am., 32, 789, 10.1016/j.idc.2018.06.003 · DOI
- Vuong, 2004, Polysaccharide Intercellular Adhesin (PIA) Protects Staphylococcus Epidermidis against Major Components of the Human Innate Immune System, Cell. Microbiol., 6, 269, 10.1046/j.1462-5822.2004.00367.x · DOI · Paper page
- Leroy, 2012, Vascular Graft Infections, Curr. Opin. Infect. Dis., 25, 154, 10.1097/QCO.0b013e3283501853 · DOI
- Palau, 2024, Antibiotic Efficacy against Methicillin-Susceptible Staphylococcus Aureus Biofilms on Synthetic and Biological Vascular Grafts, Ann. Vasc. Surg., 108, 475, 10.1016/j.avsg.2024.05.038 · doi:10.1016/j.avsg.2024.05.038
- Lee, 2015, Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone, JAMA Intern. Med., 175, 1839, 10.1001/jamainternmed.2015.5389 · DOI · Paper page
- Sixt, 2022, Long-Term Prognosis Following Vascular Graft Infection: A 10-Year Cohort Study, Open Forum Infect. Dis., 9, ofac054, 10.1093/ofid/ofac054 · DOI
- Bauer, 2024, Enterococcus-Related Vascular Graft Infection: A Case Series, Infect. Dis. Now, 54, 104940, 10.1016/j.idnow.2024.104940 · DOI
- Osada, 1999, Prophylaxis of Local Vascular Graft Infection with Levofloxacin Incorporated into Albumin-Sealed Dacron Graft (LVFX-ALB Graft), Microbiol. Immunol., 43, 317, 10.1111/j.1348-0421.1999.tb02411.x · doi:10.1111/j.1348-0421.1999.tb02411.x
- Baddour, 2014, Global and Regional Burden of Infective Endocarditis, 1990-2010: A Systematic Review of the Literature, Glob. Heart, 9, 131, 10.1016/j.gheart.2014.01.002 · DOI · Paper page
- Lauten, 2021, Bacterial Biofilms in Infective Endocarditis: An in Vitro Model to Investigate Emerging Technologies of Antimicrobial Cardiovascular Device Coatings, Clin. Res. Cardiol., 110, 323, 10.1007/s00392-020-01669-y · DOI
- Kouijzer, J.J.P., Noordermeer, D.J., van Leeuwen, W.J., Verkaik, N.J., and Lattwein, K.R. (2022). Native Valve, Prosthetic Valve, and Cardiac Device-Related Infective Endocarditis: A Review and Update on Current Innovative Diagnostic and Therapeutic Strategies. Front. Cell Dev. Biol., 10. · DOI
- Jung, 2012, Platelets Enhance Biofilm Formation and Resistance of Endocarditis-Inducing Streptococci on the Injured Heart Valve, J. Infect. Dis., 205, 1066, 10.1093/infdis/jis021 · DOI
- Delgado, 2023, 2023 ESC Guidelines for the Management of Endocarditis, Eur. Heart J., 44, 3948, 10.1093/eurheartj/ehad193 · DOI · Paper page
- Iversen, 2019, Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis, N. Engl. J. Med., 380, 415, 10.1056/NEJMoa1808312 · DOI · Paper page
- Bundgaard, 2019, Long-Term Outcomes of Partial Oral Treatment of Endocarditis, N. Engl. J. Med., 380, 1373, 10.1056/NEJMc1902096 · DOI
- Wiingaard, 2022, Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial, N. Engl. J. Med., 386, 601, 10.1056/NEJMc2114046 · doi:10.1056/nejmc2114046
- Cremieux, 1989, Evaluation of Antibiotic Diffusion into Cardiac Vegetations by Quantitative Autoradiography, J. Infect. Dis., 159, 938, 10.1093/infdis/159.5.938 · DOI · Paper page
- McAllister, 2019, Global, Regional, and National Estimates of Pneumonia Morbidity and Mortality in Children Younger than 5 Years between 2000 and 2015: A Systematic Analysis, Lancet Glob. Health, 7, e47, 10.1016/S2214-109X(18)30408-X · DOI · Paper page
- Ding, 2021, Pulmonary Biofilm-Based Chronic Infections and Inhaled Treatment Strategies, Int. J. Pharm., 604, 120768, 10.1016/j.ijpharm.2021.120768 · DOI
- Kolpen, 2022, Bacterial Biofilms Predominate in Both Acute and Chronic Human Lung Infections, Thorax, 77, 1015, 10.1136/thoraxjnl-2021-217576 · DOI · Paper page
- Short, B., Williams, C., Litherland, G., Lundy, F., Mackay, W., and Ramage, G. (2020). Development and Characterisation of a Multi-Species COPD Biofilm. Eur. Respir. J., 56. · doi:10.1183/13993003.congress-2020.2053
- Short, 2024, Informed Development of a Multi-Species Biofilm in Chronic Obstructive Pulmonary Disease, APMIS Acta Pathol. Microbiol. Immunol. Scand., 132, 336, 10.1111/apm.13386 · DOI
- Ciofu, 2010, Pseudomonas Aeruginosa Biofilms in Cystic Fibrosis, Future Microbiol., 5, 1663, 10.2217/fmb.10.125 · DOI · Paper page
- Diaconu, 2018, Endotracheal Tube Biofilm and Its Impact on the Pathogenesis of Ventilator-Associated Pneumonia, J. Crit. Care Med. Univ. Med. Si Farm. Din Targu-Mures, 4, 50
- Pirrone, 2016, Microbiome, Biofilms, and Pneumonia in the ICU, Curr. Opin. Infect. Dis., 29, 160, 10.1097/QCO.0000000000000255 · DOI
- Inglis, 1989, Tracheal Tube Biofilm as a Source of Bacterial Colonization of the Lung, J. Clin. Microbiol., 27, 2014, 10.1128/jcm.27.9.2014-2018.1989 · DOI · Paper page
- Adair, 1999, Implications of Endotracheal Tube Biofilm for Ventilator-Associated Pneumonia, Intensive Care Med., 25, 1072, 10.1007/s001340051014 · DOI · Paper page
- Vandecandelaere, I., Matthijs, N., Van Nieuwerburgh, F., Deforce, D., Vosters, P., De Bus, L., Nelis, H.J., Depuydt, P., and Coenye, T. (2012). Assessment of Microbial Diversity in Biofilms Recovered from Endotracheal Tubes Using Culture Dependent and Independent Approaches. PLoS ONE, 7. · DOI
- Vandecandelaere, 2013, The Presence of Antibiotic-Resistant Nosocomial Pathogens in Endotracheal Tube Biofilms and Corresponding Surveillance Cultures, Pathog. Dis., 69, 142, 10.1111/2049-632X.12100 · DOI
- Pneumatikos, 2009, Ventilator-Associated Pneumonia or Endotracheal Tube-Associated Pneumonia? An Approach to the Pathogenesis and Preventive Strategies Emphasizing the Importance of Endotracheal Tube, Anesthesiology, 110, 673, 10.1097/ALN.0b013e31819868e0 · DOI · Paper page
- Vandecandelaere, 2015, Microbial Composition and Antibiotic Resistance of Biofilms Recovered from Endotracheal Tubes of Mechanically Ventilated Patients, Adv. Exp. Med. Biol., 830, 137, 10.1007/978-3-319-11038-7_9 · DOI
- Restrepo, 2013, Comparison of the Bacterial Etiology of Early-Onset and Late-Onset Ventilator-Associated Pneumonia in Subjects Enrolled in 2 Large Clinical Studies, Respir. Care, 58, 1220, 10.4187/respcare.02173 · DOI
- Boltey, 2017, 5 Nursing Strategies to Prevent Ventilator-Associated Pneumonia, Am. Nurse Today, 12, 42
- Klompas, 2022, Strategies to Prevent Ventilator-Associated Pneumonia, Ventilator-Associated Events, and Nonventilator Hospital-Acquired Pneumonia in Acute-Care Hospitals: 2022 Update, Infect. Control Hosp. Epidemiol., 43, 687, 10.1017/ice.2022.88 · DOI · Paper page
- Mokrani, 2023, Antibiotic Stewardship in the ICU: Time to Shift into Overdrive, Ann. Intensive Care, 13, 39, 10.1186/s13613-023-01134-9 · DOI
- Ture, 2023, Antimicrobial Stewardship in the Intensive Care Unit, J. Intensive Med., 3, 244, 10.1016/j.jointm.2022.10.001 · DOI
- Geremia, 2024, Impact of Infection Control Measures and Antibiotic Stewardship Programs on Multidrug-Resistant Klebsiella Pneumoniae Prevalence in Intensive Care Unit, Infect. Dis. Trop. Med., 10, e1413
- Shams, 2005, Guide to Selection of Fluoroquinolones in Patients with Lower Respiratory Tract Infections, Drugs, 65, 949, 10.2165/00003495-200565070-00004 · doi:10.2165/00003495-200565070-00004
- Wise, 1991, Comparative Penetration of Selected Fluoroquinolones into Respiratory Tract Fluids and Tissues, Am. J. Med., 91, 67S, 10.1016/0002-9343(91)90313-M · doi:10.1016/0002-9343(91)90313-m
- Usman, 2023, Synergistic Effects of Gentamicin, Cefepime, and Ciprofloxacin on Biofilm of Pseudomonas Aeruginosa, Infect. Drug Resist., 16, 5887, 10.2147/IDR.S426111 · DOI
- Han, J., Luo, J., Du, Z., Chen, Y., and Liu, T. (2023). Synergistic Effects of Baicalin and Levofloxacin Against Hypervirulent Klebsiella Pneumoniae Biofilm In Vitro. Curr. Microbiol., 80. · DOI
- Vandevelde, 2014, Antibiotic Activity against Naive and Induced Streptococcus Pneumoniae Biofilms in an in Vitro Pharmacodynamic Model, Antimicrob. Agents Chemother., 58, 1348, 10.1128/AAC.01858-13 · doi:10.1128/aac.01858-13
- Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis., ciae403. · DOI · Paper page
- Craddock, V.D., Steere, E.L., Harman, H., and Britt, N.S. (2023). Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant Pseudomonas Aeruginosa in an In Vitro Cystic Fibrosis Sputum Model. Antibiotics, 12. · DOI
- Millar, 2021, Delafloxacin--A Novel Fluoroquinolone for the Treatment of Ciprofloxacin-Resistant Pseudomonas Aeruginosa in Patients with Cystic Fibrosis, Clin. Respir. J., 15, 116, 10.1111/crj.13262 · DOI
- Kocsis, 2017, New Treatment Options for Lower Respiratory Tract Infections, Expert Opin. Pharmacother., 18, 1345, 10.1080/14656566.2017.1363179 · DOI
- Bauer, 2013, A Combined Pharmacodynamic Quantitative and Qualitative Model Reveals the Potent Activity of Daptomycin and Delafloxacin against Staphylococcus Aureus Biofilms, Antimicrob. Agents Chemother., 57, 2726, 10.1128/AAC.00181-13 · DOI
- Siala, 2014, Comparison of the Antibiotic Activities of Daptomycin, Vancomycin, and the Investigational Fluoroquinolone Delafloxacin against Biofilms from Staphylococcus Aureus Clinical Isolates, Antimicrob. Agents Chemother., 58, 6385, 10.1128/AAC.03482-14 · DOI
- Kara, A., Massaro, C., Giammanco, G.M., Alduina, R., and Boussoualim, N. (2024). Phylogenetic Diversity, Antibiotic Resistance, and Virulence of Escherichia Coli Strains from Urinary Tract Infections in Algeria. Antibiotics, 13. · DOI
- David, A., Tahrioui, A., Tareau, A.-S., Forge, A., Gonzalez, M., Bouffartigues, E., Lesouhaitier, O., and Chevalier, S. (2024). Pseudomonas Aeruginosa Biofilm Lifecycle: Involvement of Mechanical Constraints and Timeline of Matrix Production. Antibiotics, 13. · DOI
- Chakrabarty, 2022, Targeting Microbial Bio-Film: An Update on MDR Gram-Negative Bio-Film Producers Causing Catheter-Associated Urinary Tract Infections, Appl. Biochem. Biotechnol., 194, 2796, 10.1007/s12010-021-03711-9 · DOI
- Ronald, 2002, The Etiology of Urinary Tract Infection: Traditional and Emerging Pathogens, Am. J. Med., 113, 14, 10.1016/S0002-9343(02)01055-0 · DOI · Paper page
- Nielsen, D.W., Klimavicz, J.S., Cavender, T., Wannemuehler, Y., Barbieri, N.L., Nolan, L.K., and Logue, C.M. (2018). The Impact of Media, Phylogenetic Classification, and E. Coli Pathotypes on Biofilm Formation in Extraintestinal and Commensal E. Coli From Humans and Animals. Front. Microbiol., 9. · DOI
- Mirzahosseini, 2023, Correlation of Biofilm Formation, Virulence Factors, and Phylogenetic Groups among Escherichia Coli Strains Causing Urinary Tract Infection: A Global Systematic Review and Meta-Analysis, J. Res. Med. Sci., 28, 66
- Wang, 2013, Bacterial Characteristics and Glycemic Control in Diabetic Patients with Escherichia Coli Urinary Tract Infection, J. Microbiol. Immunol. Infect. Wei Mian Yu Gan Ran Za Zhi, 46, 24, 10.1016/j.jmii.2011.12.024 · DOI
- Mittal, 2015, Biofilm and Multidrug Resistance in Uropathogenic Escherichia Coli, Pathog. Glob. Health, 109, 26, 10.1179/2047773215Y.0000000001 · doi:10.1179/2047773215y.0000000001
- Egbule, 2024, Assessment of Biofilm Forming Capability and Antibiotic Resistance in Proteus Mirabilis Colonizing Indwelling Catheter, Pak. J. Biol. Sci. PJBS, 27, 268, 10.3923/pjbs.2024.268.275 · doi:10.3923/pjbs.2024.268.275
- Jacobsen, 2011, Proteus Mirabilis Biofilms and Catheter-Associated Urinary Tract Infections, Virulence, 2, 460, 10.4161/viru.2.5.17783 · DOI · Paper page
- Li, L., Gao, X., Li, M., Liu, Y., Ma, J., Wang, X., Yu, Z., Cheng, W., Zhang, W., and Sun, H. (2024). Relationship between Biofilm Formation and Antibiotic Resistance of Klebsiella Pneumoniae and Updates on Antibiofilm Therapeutic Strategies. Front. Cell. Infect. Microbiol., 14. · DOI
- Rastegar, 2023, Quinolone Resistance and Biofilm Formation Capability of Uropathogenic Escherichia Coli Isolates from an Iranian Inpatients’ Population, Mol. Biol. Rep., 50, 8073, 10.1007/s11033-023-08704-x · doi:10.1007/s11033-023-08704-x
- Giovagnorio, F., De Vito, A., Madeddu, G., Parisi, S.G., and Geremia, N. (2023). Resistance in Pseudomonas Aeruginosa: A Narrative Review of Antibiogram Interpretation and Emerging Treatments. Antibiotics, 12. · DOI
- Aniba, R., Dihmane, A., Raqraq, H., Ressmi, A., Nayme, K., Timinouni, M., and Barguigua, A. (2024). Molecular and Phenotypic Characterization of Biofilm Formation and Antimicrobial Resistance Patterns of Uropathogenic Staphylococcus Haemolyticus Isolates in Casablanca, Morocco. Diagn. Microbiol. Infect. Dis., 110. · doi:10.1016/j.diagmicrobio.2024.116483
- Raya, S., Belbase, A., Dhakal, L., Govinda Prajapati, K., Baidya, R., and Kishor Bimali, N. (2019). In-Vitro Biofilm Formation and Antimicrobial Resistance of Escherichia Coli in Diabetic and Nondiabetic Patients. BioMed Res. Int., 2019. · DOI
- Colpan, 2013, Escherichia Coli Sequence Type 131 (ST131) Subclone H30 as an Emergent Multidrug-Resistant Pathogen among US Veterans, Clin. Infect. Dis., 57, 1256, 10.1093/cid/cit503 · DOI · Paper page
- Elhosseini, M.A., El-Banna, T.E., Sonbol, F.I., and El-Bouseary, M.M. (2024). Potential Antivirulence Activity of Sub-Inhibitory Concentrations of Ciprofloxacin against Proteus Mirabilis Isolates: An in-Vitro and in-Vivo Study. Ann. Clin. Microbiol. Antimicrob., 23. · DOI
- Wasfi, 2012, Antimicrobial Activities against Biofilm Formed by Proteus Mirabilis Isolates from Wound and Urinary Tract Infections, Indian J. Med. Microbiol., 30, 76, 10.4103/0255-0857.93044 · doi:10.4103/0255-0857.93044
- Whelan, S., O’Grady, M.C., Corcoran, G.D., Finn, K., and Lucey, B. (2022). Effect of Sub-Inhibitory Concentrations of Nitrofurantoin, Ciprofloxacin, and Trimethoprim on In Vitro Biofilm Formation in Uropathogenic Escherichia Coli (UPEC). Med. Sci., 11. · DOI
- Robino, 2017, Effect of Different Antibiotics on Biofilm Produced by Uropathogenic Escherichia Coli Isolated from Children with Urinary Tract Infection, Pathog. Dis., 75, ftx053
- Rafaque, 2020, In-Vitro Investigation of Antibiotics Efficacy Against Uropathogenic Escherichia Coli Biofilms and Antibiotic Induced Biofilm Formation at Sub-Minimum Inhibitory Concentration of Ciprofloxacin, Infect. Drug Resist., 13, 2801, 10.2147/IDR.S258355 · doi:10.2147/idr.s258355
- Slade-Vitković, M., Batarilo, I., Bielen, L., Maravić-Vlahoviček, G., and Bedenić, B. (2024). In Vitro Antibiofilm Activity of Fosfomycin Alone and in Combination with Other Antibiotics against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas Aeruginosa. Pharmaceuticals, 17. · DOI
- Saini, 2015, Azithromycin and Ciprofloxacin: A Possible Synergistic Combination against Pseudomonas Aeruginosa Biofilm-Associated Urinary Tract Infections, Int. J. Antimicrob. Agents, 45, 359, 10.1016/j.ijantimicag.2014.11.008 · doi:10.1016/j.ijantimicag.2014.11.008
- Wang, 2024, The Potentiation Activity of Azithromycin in Combination with Colistin or Levofloxacin Against Pseudomonas Aeruginosa Biofilm Infection, Infect. Drug Resist., 17, 1259, 10.2147/IDR.S438576 · DOI
- Zeng, B., Li, Y., Khan, N., Su, A., Yang, Y., Mi, P., Jiang, B., Liang, Y., and Duan, L. (2024). Yin-Yang: Two Sides of Extracellular Vesicles in Inflammatory Diseases. J. Nanobiotechnol., 22. · DOI
- Kanwal, 2022, Synthesis and Characterization of Carbon Dots Coated CaCO3 Nanocarrier for Levofloxacin Against Multidrug Resistance Extended-Spectrum Beta-Lactamase Escherichia Coli of Urinary Tract Infection Origin, Microb. Drug Resist. Larchmt. N, 28, 106, 10.1089/mdr.2020.0621 · doi:10.1089/mdr.2020.0621
- Pekmezovic, 2019, Host–Pathogen Interactions during Female Genital Tract Infections, Trends Microbiol., 27, 982, 10.1016/j.tim.2019.07.006 · DOI
- Pan, J., Singh, A., Hanning, K., Hicks, J., and Williamson, A. (2024). A Role for the ATP-Dependent DNA Ligase Lig E of Neisseria Gonorrhoeae in Biofilm Formation. BMC Microbiol., 24. · DOI · Paper page
- Goldstein, 2024, Impact of Molecular Ciprofloxacin Resistance Testing in Management of Gonorrhoea in a Large Urban Clinic, Sex. Transm. Infect., 100, 226, 10.1136/sextrans-2023-056099 · doi:10.1136/sextrans-2023-056099
- Collins, 2024, Target-Mediated Fluoroquinolone Resistance in Neisseria Gonorrhoeae: Actions of Ciprofloxacin against Gyrase and Topoisomerase IV, ACS Infect. Dis., 10, 1351, 10.1021/acsinfecdis.4c00041 · DOI
- Kagawa, 2024, Molecular Epidemiological and Antimicrobial-Resistant Mechanisms Analysis of Prolonged Neisseria Gonorrhoeae Collection between 1971 and 2005 in Japan, JAC-Antimicrob. Resist., 6, dlae040, 10.1093/jacamr/dlae040 · DOI
- Yueyue, 2022, Pathogenicity and Virulence of Mycoplasma Genitalium: Unraveling Ariadne’s Thread, Virulence, 13, 1161, 10.1080/21505594.2022.2095741 · DOI
- Evsyutina, D.V., Semashko, T.A., Galyamina, M.A., Kovalchuk, S.I., Ziganshin, R.H., Ladygina, V.G., Fisunov, G.Y., and Pobeguts, O.V. (2022). Molecular Basis of the Slow Growth of Mycoplasma Hominis on Different Energy Sources. Front. Cell. Infect. Microbiol., 12. · doi:10.3389/fcimb.2022.918557
- Hackett, A., Yossepowitch, O., Goor, Y., Sheffer, R., Schwartz, O., Sheftel, Y., Weiss, Y., and Maor, Y. (2024). Prevalence and Risk Factors for Antimicrobial Resistance of Mycoplasma Genitalium Infections in a High-Risk Population. J. Clin. Med., 13. · DOI
- Ertl, 2024, Concurrent parC and gyrA Fluoroquinolone Resistance Mutations and Associated Strains in Mycoplasma Genitalium in Queensland, Australia, J. Antimicrob. Chemother., 79, 467, 10.1093/jac/dkad373 · DOI
- Rowlands, 2021, A Requirement for Flow to Enable the Development of Ureaplasma Parvum Biofilms in Vitro, J. Appl. Microbiol., 131, 2579, 10.1111/jam.15120 · DOI
- Wu, 2024, Trends of Fluoroquinolones Resistance in Mycoplasma and Ureaplasma Urogenital Isolates: Systematic Review and Meta-Analysis, J. Glob. Antimicrob. Resist., 36, 13, 10.1016/j.jgar.2023.11.007 · DOI
- Garcia, 2024, Phase Variable Colony Variants Are Conserved across Gardnerella Spp. and Exhibit Different Virulence-Associated Phenotypes, mSphere, 9, e0045024, 10.1128/msphere.00450-24 · DOI
- Swidsinski, 2011, Response of Gardnerella Vaginalis Biofilm to 5 Days of Moxifloxacin Treatment, FEMS Immunol. Med. Microbiol., 61, 41, 10.1111/j.1574-695X.2010.00743.x · DOI
- Esposito, 2017, Diagnosis and Management of Skin and Soft-Tissue Infections (SSTI). A Literature Review and Consensus Statement: An Update, J. Chemother. Florence Italy, 29, 197, 10.1080/1120009X.2017.1311398 · DOI
200 of 233 shown
Cited by
Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms
Touaitia, R., Mairi, A., Ibrahim, N. A., Basher, N. S., Idres, T., & Touati, A. (2025) · Antibiotics · doi:10.3390/antibiotics14050470 · Cited by 273
Metadata
- Authors
- Geremia, N., Giovagnorio, F., Colpani, A., De Vito, A., Botan, A., Stroffolini, G., Toc, D.-A., Zerbato, V., Principe, L., Madeddu, G., Luzzati, R., Parisi, S. G., & Di Bella, S.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2024-12-11
- Volume
- 17
- Issue
- 12
- Pages
- 1673
- ISSN
- 1424-8247
- Cited by
- 42
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.